The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 36, No. 10, pp. 1614-1619. DOI 10.1345/aph.1A256
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McQueen, A.
Right arrow Articles by Baroletti, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McQueen, A.
Right arrow Articles by Baroletti, S.


Research Articles

Adjuvant ketamine analgesia for the management of cancer pain

AL McQueen and SA Baroletti

OBJECTIVE: To review the clinical literature evaluating the utilization of intravenous ketamine for the management of cancer-related pain, to summarize the data that suggest ketamine is an appropriate adjuvant method of providing analgesia and to report a case of successful pain management using ketamine in a patient with recurrent testicular cancer at our institution. DATA SOURCES: Primary literature was identified through a MEDLINE search (1966-March 2002), and additional information was obtained through secondary and tertiary sources. DATA SYNTHESIS: The available data suggest that supplementation of morphine with ketamine improves analgesia in patients with cancer, and also provides insight to the controversy regarding the efficacy and adverse effects of various ketamine doses. At subanesthetic doses, ketamine may be beneficial at reducing opioid requirements and related adverse effects. CASE SUMMARY: A 34-year-old white man with recurrent testicular cancer was admitted with radiating neuropathic pain of the legs and lower back. The patient was suspected to also be experiencing opioid adverse effects; therefore, alternative analgesic options were warranted. Ketamine was successful in reducing patient-reported pain and was also well tolerated. CONCLUSIONS: Ketamine is an adjuvant analgesic for the treatment of cancer-related pain when other agents either fail or are intolerable. Accordingly, there are several factors that may prevent adequate pain control with opioid use; therefore, alternative analgesic options should be considered. Promise exists for ketamine as a contemporary analgesic in the appropriate patient.


This article has been cited by other articles:


Home page
Br J AnaesthHome page
J. Benrath, G. Scharbert, B. Gustorff, H.-A. Adams, and H. G. Kress
Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain
Br. J. Anaesth., August 1, 2005; 95(2): 247 - 249.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
K. Subramaniam, B. Subramaniam, and R. A. Steinbrook
Ketamine as Adjuvant Analgesic to Opioids: A Quantitative and Qualitative Systematic Review
Anesth. Analg., August 1, 2004; 99(2): 482 - 495.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
Correction
Ann. Pharmacother., September 1, 2003; 37(9): 1346 - 1346.
[Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.